Diurnal salivary androstenedione and 17-hydroxyprogesterone levels in healthy volunteers for monitoring treatment efficacy of patients with congenital adrenal hyperplasia.

ABSTRACT:

Objective

Treatment of congenital adrenal hyperplasia (CAH) patients with glucocorticoids is often challenging since there is a delicate balance between over- and undertreatment. Treatment can be monitored noninvasively by measuring salivary androstenedione (A4) and 17-hydroxyprogesterone (17-OHP). Optimal treatment monitoring requires the establishment of reference values in saliva.

Design

A descriptive study.

Patients

For this study saliva of 255 healthy paediatric and adult volunteers with an age range of 4-75 years old was used.

Measurements

We developed a sensitive liquid chromatography-tandem mass spectrometry method, assessed salivary A4 and 17-OHP stability, and measured A4 and 17-OHP concentrations in saliva collected in the morning, afternoon, and eve

SUBMITTER: Adriaansen BPH 

PROVIDER: S-EPMC9542109 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature